Comparison of Dermal and Systemic Application of Glucocorticoids on the RM 3/1&lt;sup&gt;+&lt;/sup&gt; Macrophage in Human Blood

Zwadlo-Klarwasser, Gabriele; Bent, Stefan; Schmutzler, W.

doi:10.1159/000235383

Cited by 2 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This special responsiveness of psoriatic monocytes to alternative macrophage activators may be another reason why we have found that psoriatic macrophages display an alternatively activated macrophage phenotype. Confirming this notion, expression of the alternative macrophage antigen RM 3/1 has been shown to be considerably elevated on peripheral blood monocytes of a single PSO patient [67].…”

Section: Discussionmentioning

confidence: 66%

Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+++, MS-1± 25F9−) in psoriatic dermis

et al. 1996

View full text Add to dashboard Cite

Immunological mechanisms play an important role in the pathogenesis of psoriasis. Lesional psoriatic skin-derived T-cell clones have been shown to stimulate keratinocyte proliferation and to predominantly express a T-helper type 1 cytokine pattern. However, T-helper type 2-like cytokines have also been identified in some psoriatic T-cell clones. In parallel to the T-helper type 1/type 2 dichotomy, a distinction between interferon-gamma-induced (classically activated) macrophages and interleukin-4/glucocorticoid-induced (alternatively activated) macrophages has been put forward as a conceptual framework for a better understanding of immunopathological processes. In the present study, the phenotype of mononuclear phagocytes in psoriatic skin lesions (n = 21), allergic contact dermatitis (n = 4) and normal skin (n = 2) was investigated using a panel of monoclonal antibodies (mAb) against monocytes/macrophages and dendritic cells (mAb MS-1, RM 3/1, and 25F9 against subsets of in vitro alternatively activated macrophages, and mAb against myeloid antigens CD1a, CD11b, CD11c, CD34, CD36, and CD68). With regard to mononuclear phagocytes, psoriatic skin was found to be compartmentalized into epidermis, subepidermal space, and upper and lower dermis. RM 3/1++ +, MS-1+/-, 25F9- dendritic macrophages previously classified as type II alternatively activated macrophages were the dominant dermal macrophage population in psoriatic skin, while intraepidermal and epithelium-lining macrophages expressed a different, presumably classically activated, macrophage phenotype (RM 3/1-, MS-1-, 25F9-, CD68+2, CD11b+2). In allergic contact dermatitis, a classical T-helper type 1 disease, RM 3/1++ + macrophages were less prominent. Since MS-1 high molecular weight protein is much more sensitive to interferon-gamma-induced suppression than RM 3/1 antigen, a predominance of T-helper type 1 cytokines in psoriasis could explain why dermal dendritic macrophages do not express the fully induced MS-1++ +, RM 3/1++ +, 25F9+/- phenotype of type I alternatively activated macrophages.

show abstract

Section: Discussionmentioning

confidence: 66%

Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+++, MS-1± 25F9−) in psoriatic dermis

et al. 1996

View full text Add to dashboard Cite

show abstract

“…Administration of glucocorticoids either intravenously, subcutaneously or dermally but also endogenous cortisol induced by major trauma, e.g. severe burn injuries, cause the formation of RM 3/1 monocytes in blood [5][6][7]14]. Therefore monitoring of the expression of RM 3/1 monocytes was used as a parameter to evaluate the anti-inflammatory efficacy of glucocorticoids.…”

Section: Discussionmentioning

confidence: 99%

“…Using different glucocorticoids and routes of administration, e.g. intravenous, subcutaneous or dermal, so far only dermal application revealed a clearly dose-dependent difference between glucocorticoids [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

The Effects of the Glucocorticoids Prednisolone, Deflazacort and Beclomethasone-Dipropionate on the RM 3/1 Macrophage in Human Peripheral Blood

Zwadlo-Klarwasser

Schmutzler²

1998

Skin Pharmacol Physiol

Self Cite

View full text Add to dashboard Cite

Different glucocorticoids (GC) applied intravenously, subcutaneously or in vitro exert only small differences in the ability to raise RM 3/1 macrophages from human blood monocytes. Dermal application however reveals a dose-dependent difference between GC. The present experiments were designed to study the efficacy of oral and topical application in this model. We also intended to obtain some information about the qualitative differences between the effects of prednisolone and deflazacort, which was reported to cause less adverse reactions than other GC. Both GC were orally administered to probands in doses regarded as equivalent with respect to general GC effects by the manufacturers of deflazacort (5–6 mg or multiples). A single dose of 5 mg prednisolone had no effect; 50 mg increased the number of RM 3/1 macrophages within 12 h from a basal level of 8.5% to about 80% similar to an intravenous or subcutaneous administration of GC. 10 mg prednisolone enhanced the number of RM 3/1 macrophages also within 12 h, reaching a mean maximum of about 60% at 24 h, declining thereafter. 12 mg deflazacort raised the number of RM 3/1 macrophages much slower, reaching a maximum of 30% (average) after 48 h. The interindividual variation was found to be mainly the time lag between dosage and maximum effect. Interindividual differences of prednisolone effects concerned mainly the maximal increase of RM 3/1 macrophages after 24 h. These results show that in this test system deflazacort was found to be less effective than expected. To elucidate the topical influence of GC, probands inhaled twice daily 0.5 mg beclomethasone-dipropionate over a period of 11 days. No effect on the number of RM 3/1 macrophages was observed, suggesting that beclomethasone applied in this dose did not cause systemic GC reactions.

show abstract

Comparison of Dermal and Systemic Application of Glucocorticoids on the RM 3/1<sup>+</sup> Macrophage in Human Blood

Cited by 2 publications

References 2 publications

Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+++, MS-1± 25F9−) in psoriatic dermis

Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+++, MS-1± 25F9−) in psoriatic dermis

The Effects of the Glucocorticoids Prednisolone, Deflazacort and Beclomethasone-Dipropionate on the RM 3/1 Macrophage in Human Peripheral Blood

Contact Info

Product

Resources

About